Patents by Inventor Steven Neville Chatfield
Steven Neville Chatfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100322955Abstract: A series of genes from Salmonella typhimurium are shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.Type: ApplicationFiled: May 28, 2009Publication date: December 23, 2010Inventor: Steven Neville Chatfield
-
Patent number: 7323183Abstract: There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan.Type: GrantFiled: May 8, 2002Date of Patent: January 29, 2008Assignee: Archimedes Development LimitedInventors: Lisbeth Illum, Steven Neville Chatfield
-
Patent number: 6905691Abstract: The invention relates to a vaccine comprising a bacterium attenuated by a non-reverting mutation in a gene encoding a protein which promotes folding of extracytoplasmic proteins. Such mutations were initially identified as being useful in vaccines from a bank of randomly inserted, transposon mutants in which attenuation was determined as a reduction in virulence of the organism in the mouse model of infection. Site directed mutation of the gene results in a strain which shows at least 4 logs of attenuation when delivered both orally and intravenously. Animals vaccinated with such a strain are protected against subsequent challenge with the parent wild type strain. Finally, heterologous antigens such as the non-toxic and protective, binding domain from tetanus toxin, fragment C, can be delivered via the mucosal immune system using such strains of bacteria. This results in the induction of a fully protective immune response to subsequent challenge with native tetanus toxin.Type: GrantFiled: June 9, 2000Date of Patent: June 14, 2005Assignee: Celltech Pharma Europe LimitedInventors: Steven Neville Chatfield, Gordon Dougan, Mark Sydenham
-
Patent number: 6902906Abstract: The invention provides a bacterium attenuated by a non-reverting mutation in each of the aroC gene, the ompF gene and the ompC gene. The bacterium is useful as a vaccine. The bacterium may, for example, be an attenuated strain of E. coli useful in vaccination against diarrhoea.Type: GrantFiled: March 25, 1999Date of Patent: June 7, 2005Assignee: Acambis Research LimitedInventor: Steven Neville Chatfield
-
Publication number: 20040258709Abstract: The present invention provides a polypeptide comprising tetanus toxin fragment C, or a fragment thereof, fused to the pre-S1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the pre-S2 region of HBV or a fragment thereof. It also provides vaccine compositions comprising the polypeptide of the invention.Type: ApplicationFiled: July 15, 2004Publication date: December 23, 2004Applicant: Medeva Europe LimitedInventor: Steven Neville Chatfield
-
Publication number: 20040131637Abstract: The ssaG derived from Salmonella is shown to exert improved expression of heterologous genes compared to other known promoters and therefore can be used advantageously in constructs for the delivery of therapeutic proteins to a patient.Type: ApplicationFiled: February 26, 2004Publication date: July 8, 2004Inventor: Steven Neville Chatfield
-
Patent number: 6699480Abstract: The invention provides the use of Hepatitis A virus capsid, or a mucosally immunogenic fragment or epitope thereof, for the manufacture of a mucosal vaccine composition for administration to a mucosal surface of a patient to induce production of serum Immunoglobulin G antibody against Hepatitis A. Preferably the vaccine composition is administered by the intranasal route.Type: GrantFiled: May 1, 2001Date of Patent: March 2, 2004Assignee: Medeva Holdings BVInventors: Steven Neville Chatfield, Mark Roberts
-
Patent number: 6680182Abstract: The invention provides a DNA molecule comprising a promoter sequence operably linked to a DNA sequence encoding first and second proteins linked by a hinge region wherein in that the promoter sequence can be one having activity which is induced in response to a change in the surrounding environment and the first protein can be Tetanus toxin C fragment or one or more epitopes thereof. The invention also provides intermediate molecules having a promoter operably linked to a DNA sequence encoding a first antigenic sequence and a hinge region, and at or adjacent the 3′-end thereof one or more restriction sites for the introduction of a second anti-genic sequence. In addition, the invention provides replicable expression vectors containing the DNA fusion proteins expressed therefrom, bacterial transformed with the vectors and the use of the bacteria, in vaccines.Type: GrantFiled: July 21, 1995Date of Patent: January 20, 2004Assignee: Acambis Research LimitedInventors: Mohammed Anjam Khan, Bernardo Villarreal-Ramos, Carlos Estenio Hormaeche, Steven Neville Chatfield, Gordon Dougan
-
Publication number: 20030157121Abstract: A series of genes from Salmonella typhimurium are shown to encode products which are implicated in virulence. The identification of these genes threfore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.Type: ApplicationFiled: July 29, 2002Publication date: August 21, 2003Inventor: Steven Neville Chatfield
-
Publication number: 20030039665Abstract: There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan.Type: ApplicationFiled: May 8, 2002Publication date: February 27, 2003Applicant: West Pharmaceutical Services Drug Delivery & Clinical Research Centre LimitedInventors: Lisbeth Illum, Steven Neville Chatfield
-
Publication number: 20030007979Abstract: The invention provides the use of Hepatitis A virus capsid, or a mucosally immunogenic fragment or epitope thereof, for the manufacture of a mucosal vaccine composition for administration to a mucosal surface of a patient to induce production of serum Immunoglobulin G antibody against Hepatitis A. Preferably the vaccine composition is administered by the intranasal route.Type: ApplicationFiled: May 1, 2001Publication date: January 9, 2003Inventors: Steven Neville Chatfield, Mark Roberts
-
Patent number: 6488926Abstract: The invention provides a DNA construct comprising a DNA sequence encoding a fusion protein of the formula: TetC-(Z)a-Het, wherein: TetC is the C fragment of tetanus toxin, or a protein comprising the epitopes thereof; Het is a heterologous protein, Z is an amino acid, and a is zero or a positive integer, provided that (Z)a does not include the sequence Gly-Pro. The invention also provides replicable expression vectors containing the constructs, bacteria transformed with the constructs, the fusion proteins per se and vaccine compositions formed from the fusion proteins or attenuated bacteria expressing the fusion proteins.Type: GrantFiled: July 19, 1996Date of Patent: December 3, 2002Assignee: Medeva Holdings B.V.Inventors: Mohammed Anjam Khan, Carlos Estenio Hormaeche, Steven Neville Chatfield, Gordon Dougan
-
Patent number: 6391318Abstract: A variety of different types of nasal vaccine systems have been described including cholera toxin, microspheres, nanoparticles, liposomes, attenuated virus, and outer membrane proteins (proteosomes). The present invention is directed toward a novel nasal vaccine composition that utilizes the cationic polysaccharide, chitosan, as a delivery system. Chitosan is a polysaccharide comprising copolymers of glucosamine and N-acetylglucosamine. The term chitosan encompasses a series of chitosan polymers with different molecular weights (50 kDa-2,000 kDa) and degree of acetylation (40%-98%). Several vaccine animal studies were carried out employing influenza or pertussis antigens in combination with chitosan. Nasal administration of chitosan-antigen nasal vaccines induced significant serum IgG responses and secretory IgA levels. Animals vaccinated via the nasal route with various chitosan-antigen vaccines were also found to be protected against the appropriate challenge.Type: GrantFiled: June 1, 1998Date of Patent: May 21, 2002Assignee: West Pharmaceutical Services Drug Delivery & Clinical Research Centre LimitedInventors: Lisbeth Illum, Steven Neville Chatfield
-
Patent number: 6136606Abstract: The invention provides a vaccine composition in the form of a kit, comprising a first container containing an antigenic preparation comprising influenza antigen or antigens; and a second container containing an effective adjuvant amount of a chitosan which is a deacetylated chitin which is at least 80% deacetylated. The antigenic preparation in the first container preferably comprises haemagglutinin and neuraminidase influenza antigens.Type: GrantFiled: April 29, 1998Date of Patent: October 24, 2000Assignee: Medeva Holdings BVInventor: Steven Neville Chatfield
-
Patent number: 6129922Abstract: The invention provides the use of Hepatitis A virus capsid, or a mucosally immunogenic fragment or epitope thereof, for the manufacture of a mucosal vaccine composition for administration to a mucosal surface of a patient to induce production of serum Immunoglobulin G antibody against Hepatitis A. Preferably the vaccine composition is administered by the intranasal route.Type: GrantFiled: February 8, 1996Date of Patent: October 10, 2000Assignee: Medeva Holdings B.V.Inventors: Steven Neville Chatfield, Mark Roberts
-
Patent number: 6048536Abstract: The invention relates to a vaccine composition adapted for mucosal administration, and in particular for intranasal administration, the composition comprising an influenza virus antigen or antigens, such as haemagglutinin and neuraminidase influenza virus antigens, and an effective adjuvant amount of a chitosan. The compositions can be used to immunise a host against infection with influenza, the chitosan serving to enhance the stimulation of a protective IgA mucosal immune response and an IgG systemic immune response.Type: GrantFiled: April 2, 1997Date of Patent: April 11, 2000Assignee: Medeva Holdings BVInventor: Steven Neville Chatfield
-
Patent number: 5980907Abstract: Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a protein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encoding a heterologous antigen.Type: GrantFiled: June 5, 1995Date of Patent: November 9, 1999Assignee: Glaxo Wellcome Inc.Inventors: Gordan Dougan, Ian George Charles, Carlos Estenio Hormaeche, Kevin Stuart Johnson, Steven Neville Chatfield
-
Patent number: 5851519Abstract: The present invention discloses a novel approach to attenuating bacteria and for their use as live vaccines. The vaccines can be used in human and animal medicine.In particular, there is disclosed a method of attenuating a bacteria by mutating a gene concerned with the regulation of one or more genes concerned with expression of outer membrane proteins, particularly porin proteins.Type: GrantFiled: April 10, 1995Date of Patent: December 22, 1998Assignees: Glaxo Wellcome Inc., The Royal Society, The Lister Institute of Preventive Medicine, The University Court of The University of DundeeInventors: Gordan Dougan, Steven Neville Chatfield, Christopher Francis Higgins, Charles James Dorman
-
Patent number: 5811105Abstract: An attenuated microorganism harboring two mutated genes, each of which is located in the organisms aromatic pathway is provided. These organisms can usefully form the basis of a vaccine. They can be genetically engineered so as to express antigens from other pathogens and thus form the basis of a range of multi-valent vaccines.Type: GrantFiled: May 24, 1995Date of Patent: September 22, 1998Assignee: Glaxo Wellcome, Inc.Inventors: Gordon Dougan, Steven Neville Chatfield, Carlos Estenio Hormaeche
-
Patent number: 5804194Abstract: Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a protein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encoding a heterologous antigen.Type: GrantFiled: December 7, 1994Date of Patent: September 8, 1998Assignee: Glaxo Wellcome Inc.Inventors: Gordan Dougan, Ian George Charles, Carlos Estenio Hormaeche, Kevin Stuart Johnson, Steven Neville Chatfield